Title:
【発明の名称】ポリエチレングリコールを有するエリスロポエチン接合体
Document Type and Number:
Japanese Patent JP2003503464
Kind Code:
A
Abstract:
Erythropoietin glycoprotein products are disclosed which have the in vivo biological activity of causing bone marrow cells to increase production of reticulocytes and red blood cells. The present conjugates have an increased circulating half-life and plasma residence time, decreased clearance, and increased clinical activity in vivo. In addition, compared with conventional PEG-EPO conjugates, the conjugates of this invention have superior clinical properties. The present invention also includes a method for the treatment of anemia in a human employing the novel erythropoietin glycoprotein products as well as a method for preparing the erythropoietin glycoprotein products.
More Like This:
| WO/1993/009816 | METHOD FOR DIAGNOSING AND TREATING CANCER |
| JP2022110084 | CONTROLLED-RELEASE CNP AGONISTS WITH INCREASED NEP STABILITY |
| WO/2005/021023 | THERAPEUTICAL CONVERSION |
Inventors:
Burg joseph
Hilger Bernd
Josel Hans-Peter
Hilger Bernd
Josel Hans-Peter
Application Number:
JP2001507507A
Publication Date:
January 28, 2003
Filing Date:
June 28, 2000
Export Citation:
Assignee:
F. HOFFMANN-LA ROCHE AKTIENGESELLSCHAFT
International Classes:
A61K38/22; A61K47/48; A61P7/06; A61P13/12; A61P31/18; A61P35/00; C07K14/505; A61K38/00; (IPC1-7): A61K38/22; A61K47/48; A61P7/06; A61P13/12; A61P31/18; A61P35/00; C07K14/505
Attorney, Agent or Firm:
Shimizu Hatsushi (1 person outside)